2021-2022 NP/PA Buprenorphine Waiver Training: Includes Part I (8-Hr) & Part II (16-Hr)
Full 24-hour training course as required by the CARA Act.
Expires: 07/31/2023 (subject to change)
- CE for this activity will not be available after this date.
PLEASE READ THIS ENTIRE DESCRIPTION FULLY FOR ALL INFORMATION TO COMPLETE THIS ACTIVITY.
To qualify, NPs and PAs must:
- Be aware of any state law regarding the treatment of addiction/OUD
- Be licensed under state law to prescribe schedule III, IV, or V medications for pain
- Complete not less than 24 hours of appropriate education through a qualified provider
- Through other training or experience, demonstrate the ability to treat and manage OUD
- If required by state law, be supervised or work in collaboration with a qualified* physician to prescribe medications for the treatment of OUD
*NOTE: CARA also defers to state law regarding whether an NP or PA works with a physician through a supervisory or collaborative relationship and, where this applies, the physician must also be qualified to prescribe buprenorphine.
OverviewThis CE activity provides two training sessions that fulfill the 24-hour continuing education training requirements outlined in the Comprehensive Addiction and Recovery Act (CARA). Participants must complete both activities to qualify for the waiver application. Those who complete this educational activity must allow a week for their information to be reported and then will be able to apply for the waiver to prescribe buprenorphine for patients with opioid addiction.
ASAM, AANP and AAPA have formed a collaborative to provide the 24-hour waiver training for nurse practitioners and physician assistants. Educational content has been identified and/or created to satisfy the 24-hour requirement as described in the Comprehensive Addiction and Recovery Act (CARA).
8-hour Activity Overview: Part I: The ASAM Treatment of Opioid Use Disorder Course: The 8-hour course will ensure that participants are exposed to the highest quality, evidence-based practices when using buprenorphine to treat opioid use disorders. (Includes waiver qualifying requirements)
16-hour Activity Overview: Part II: The ASAM 16-Hour Medications for Opioid Use Disorder Course: The 16-hour course includes all additional education required by the Comprehensive Addiction and Recovery Act (CARA) for nurse practitioners to successfully apply for a waiver to prescribe buprenorphine for office-based treatment of opioid use disorders.
ObjectivesUpon completion of Part I (8-Hour) course requirements, learners will be able to:
Upon completion of Part II (16-Hour) course requirements, learners will be able to:
- Identify, assess, and diagnose patients with opioid use disorder while considering severity, chronicity, individual characteristics, and psychiatric and medical comorbidities.
- Develop an individualized, patient-centered treatment plan, including negotiating treatment goals by evaluating appropriate medication- and psychosocial-based treatment options.
- Monitor progress and modify treatment plans based on patient needs and progress toward treatment goals.
- Implement best practices for office systems, including team-based care, to support treatment with medications for opioid use disorder.
- Examine misconceptions, stigma, and complexities (bioethical, social, clinical, public health) associated with opioid use disorder and the use of medications to treat opioid use disorder.
- Examine strategies to manage patients with atypical or unusually severe presentations related to opioid withdrawal management and precipitated withdrawal.
- Understand the updated standards from the ASAM National Practice Guideline for OUD treatment and apply the updates in clinical practice.
- Explore important considerations in the initial and periodic assessment of patients with substance use disorders.
- Identify recommended best practices for treating pain in individuals with opioid use disorder.
- Explore psychosocial services and behavioral interventions for the treatment of opioid use disorder.
How to Complete This Activity
Once you have REGISTERED this course in the AANP CE Center, under Download Materials, review the instructions provided for completing this activity on the Partner site.
Participants can complete Part I or Part II or both, depending on their needs. A certificate of completion will be awarded for individual completion of Part I and Part II. Completion of both Part I and Part II is a requirement to be waivered (see below) - both Part I and Part II are included in this 24-hour CE course.
Learners will be directed to a partner site for content, and re-directed back to the AANP CE Center to complete the requirements for CE and obtain the CE Certificate.
- 8-Hour Training: Part I: The ASAM Treatment of Opioid Use Disorder Course (Includes waiver qualifying requirements)
- 16-Hour Training: Part II: The ASAM 16-Hour Medications for Opioid Use Disorder Course
Completions are reported weekly to the Center for Substance Abuse Treatment (CSAT). Learners must apply for the waiver to prescribe buprenorphine to their patients with opioid use disorders.
- Learners must log on in the Partner site and Register this course on their site to continue: 24-Hour Waiver Training: AANP
- A unique participation code will be provided at the end of the CE activity's content on the Partner site for Part I and Part II. See Instructions included in the Additional Resources area for details.
Content Developers and Speakers
|Faculty for Part I:|
- Daniel P. Alford, MD, MPH, FACP, DFASAM
- Debra Newman, PA-C, MPAS, MPH
- Yngvild K. Olsen, MD, MPH, DFASAM
- Edwin Salsitz, MD, DFASAM
- Kristin E. Smith, DNP, FNP-C
- Bernard Stuetz PA-C, MA
- Matt Tierney, APRN
- Deanna Wilson, MD, MPH
|Faculty for Part II:|
- Jeffrey DeVido, MD, MTS, FASAM
- Paul H. Earley, MD, FASAM
- Brian Hurley, MD, MBA, DFASAM
- Margaret Jarvis, MD
- Kyle Kampman, MD, FASAM
- Laura Kehoe, MD, MPH, FASAM
- Kelly Kleinert, MD
- Lewis S. Nelson, MD
- Alain H. Litwin, MD
- JoAn Laes, MD
- Michelle Lofwall, MD
- Carla Marienfeld, MD
- Yngvild K. Olsen, MD, MPH, DFASAM
- Elizabeth Salisbury-Afshar, MD, MPH, FAAFP, FACPM, DFASAM
- Sandra Springer, MD
- Sharon Stancliff, MD, FASAM
- Alaina Steck, MD
- R. Corey Waller, MD, MS, DFASAM
- Nalan Ward, MD
- Timothy J. Wiegand, MD, FACMT, FAACT, DFASAM
- Stephen Wyatt, DO, FOAAM, FASAM
This activity was planned in accordance with AANP Accreditation Standards and Policies in collaboration with ASAM, and AAPA to provide the 24 hours of required education. Planner, faculty, and all other relevant disclosures are listed on the ASAM website.
The collaborative of ASAM, AANP and AAPA identified and reviewed this content to provide the 24-hour waiver training required by CARA and SUPPORT. The 24-Hour Waiver Training is available for free through 2022 in part by an unrestricted educational grant from Indivior.
This educational activity may contain opinions of the speakers from their personal experience. The activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Individuals who have contributed to the CE Center were carefully selected for their knowledge and experience in the subject area under review. This presentation is informational only and may contain opinions of the authors from their personal experience that do not necessarily express the opinions of the American Association of Nurse Practitioners (AANP). The activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Clinical practice is a constantly changing process and new information becomes available every day. Neither AANP nor the contributing individuals can warrant that the material will continue to be accurate, nor do they warrant that the material is completely free of errors upon publication. Attendees and participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
For questions or more information concerning this online CE opportunity contact the AANP CE Center Manager at CECenter@aanp.org.
|24 Contact Hour(s) of CE,
13.25 of which may be applied towards Pharmacology